pharma news today glp-1 Lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating GLP-1 Boom Is Creating Winners

However, it did not yield significant improvements in pain perception.[64] GLP-1 receptors have also been detected in the choroid plexus, and in a rodent model, their activation was shown to reduce cerebrospinal fluid secretion and intracranial pressure (ICP).[65] In patients with idiopathic intracranial hypertension (IIH) and obesity, exenatide, semaglutide, liraglutide have been associated with a reduction in the number of headache days, and exenatide significantly reduced ICP.[66, 67] Furthermore, animal studies have indicated potential benefits of GLP-1RAs in neuropathic pain and diabetic neuropathy, although clinical evidence remains inconsistent.[64] One study reported structural improvements in the nerves of patients with diabetic neuropathy receiving semaglutide or dulaglutide, while two other studies found no significant benefit in neuropathy symptoms with liraglutide and exenatide.[6870] Additional off-label uses under investigation include neurodegenerative disorders, polycystic ovary syndrome (PCOS), and osteoporosis

Look for a product that includes Vitamin C, which is essential for collagen synthesis

Hathaway JT, Shah MP, Hathaway DB, et al

Heterogeneity of hormone expression

Various methods to inhibit the GIP system in rodents result in reduced body weight and improve insulin sensitivity (52)

The use of some of these medications for weight loss, such as Ozempic for weight loss and Wegovy for weight loss outside of approved BMI ranges, has led to serious shortages